As noted in the agency, the data obtained indicate that with the spread of the “delta” variant, the number of cases of hospitalization of adolescents increases sharply.
The European Medicines Agency (EMA) intends to study the feasibility of vaccination against coronavirus in children aged 5-11 years. This was announced on Thursday at a briefing by the head of the EMA Department for health threats and vaccination strategy, Marco Cavaleri.
According to him, the data obtained from the United States indicate that with the spread of the “delta” variant, the number of cases of hospitalization of adolescents who are not vaccinated is sharply increasing. “Two mRNA vaccines approved in the EU are allowed for use among people over 12 years of age,” the expert noted. “It is believed that the benefits of using these vaccines among adolescents outweigh the risks.”
“For children under the age of 12, we expect to receive data on at least some vaccines during the fall to understand whether the benefits of using them outweigh the risks among children aged 5-11 years,” Cavaleri said. “We will study this issue.”